MARKET WIREStockInvest.us • 23h ago
Curis Stock Price Forecast. Should You Buy CRIS?StockInvest.us report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
Why CRIS Stock surged +10.17% Today — RQD Quant Desk Flash
$0.66 +10.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.67
Curis Inc. (CRIS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $4.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CRIS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CRIS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Curis Inc. (NASDAQ: CRIS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.66 (+10.17% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CRIS compare to LIMN and BTTC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRIS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LIMN (Liminatus Pharma Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and BTTC (Black Titan Corporation) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $4.8M). Among the 5-stock peer group, CRIS leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CRIS?
▼
Per CRIS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001108205), Curis Inc. generated $9.4M in revenue (-13.4% YoY), -$7.6M in net income, and -$27.2M in free cash flow against $20.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.67 (+1.64%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRIS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY CRIS SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (22% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.61-34.4% Next Q
19
Q2 (-2Q)Grade E$0.40+0% Next Q
22
Q3 (-1Q)Grade E$0.40+65% Next Q
24
CurrentGrade E$0.66-10.3% Hist 90D α
27
Trajectory: E (19) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CRIS Turnaround Squeeze
While CRIS currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.88) and Max Pain ($0.69) forces dealer call-delta covering toward $33.39.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRIS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRIS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CRIS Stock surged +10.17% Today — RQD Quant Desk Flash
Curis Inc. (CRIS) surged +10.17% to $0.66, trading at 2% of its 52-week range ($0.33 – $31.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.33 – $31.8) with RSI-14 at 43.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.66 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: CRIS Exhibits 3.44x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live CRIS Headlines & Catalysts
MARKET WIREGuruFocus • 1d ago
Curis (CRIS) Announces $8.5M Stock and Warrant Offering to InstiGuruFocus report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
Why Curis (NASDAQ: CRIS) Stock Fell 20% After Its $8.5 Million Private Placementkalkine.ca report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 1d ago
CRIS Q2 2026 Earnings: Narrower-Than-Expected Loss, Yet Shares Slip 3.73% - Low Growth Earningshttps://www.dars.gov.et/ report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 1d ago
Curis prices USD 8.5 million offering: Curis stock gains 3.37 percentad-hoc-news.de report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.dars.gov.et • 1d ago
Curis Inc. (CRIS) Slips 6.21% to $0.61, Testing the Lower Edge of Its Range - Insider Buying Alertswww.dars.gov.et report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 1d ago
MarketBeat estimates USD 1.00 million revenue for Curis stockad-hoc-news.de report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 1d ago
Curis stock gains 3.37 percent to EUR 0.35: MarketBeat estimates a November 5 reportad-hoc-news.de report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 3d ago
12 Health Care Stocks Moving In Friday's After-Market SessionGainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor Therapeutics
MARKET WIREChartMill • 17d ago
Top US Stock Gainers and Losers in Today's SessionSee today's largest US stock movers, including OPENW up 56.63%, MDXH down 60.55%, and other notable gainers and losers from the session.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRIS)
- ✓Walkthrough of CRIS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CRIS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -94.31%▲ RESISTANCE BREAKOUT
2026-11-03O $0.55H $0.66L $0.55C $0.66VOL 915.5K
RES: $0.44SUP: $-0.17SMA50: $0.88SMA200: $8.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CRIS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -13.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CRIS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CRIS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRIS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRIS)
Health Care Rank #894 of 1015
⚔️ LIMN vs CRIS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CRIS vs. LIMN, BTTC, PMCB, CELZ)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Curis Inc. (CRIS) ranks #894 by composite RQD confidence (27/100, grade E) and #955 by equity capitalization ($4.0M). Within this direct 5-issuer industry benchmark cohort, CRIS leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with CRIS at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRIS
ACTIVE
Curis Inc. | E | 27/100 | — | — | -35.0% | +10.17% | $4.0M | Benchmark Subject |
| LIMN Liminatus Pharma Inc. (Class A) | D- | 35/100 | — | — | -35.0% | -10.64% | $3.8M | /limn-vs-cris → |
| BTTC Black Titan Corporation | D- | 38/100 | — | — | — | -3.17% | $4.8M | /bttc-vs-cris → |
| PMCB PharmaCyte Biotech Inc. | E | 34/100 | — | — | -30.2% | +2.71% | $3.2M | /pmcb-vs-cris → |
| CELZ Creative Medical Technology Holdings Inc. | E | 20/100 | — | 63.4% | -35.0% | -4.81% | $5.0M | /celz-vs-cris → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001108205 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Curis Inc. (CRIS) reported GAAP revenue of $9.4M (-13.4% vs. FY2024 revenue of $10.9M , and -5.8% cumulative change since FY2023) , GAAP net income of -$7.6M, operating cash flow of -$27.2M, and free cash flow of -$27.2M (+31.2% YoY). On the balance sheet, CRIS closed FY2025 with $20.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.4M | -$7.6M | -$27.2M | -$27.2M | $20.0M | — |
| FY2024 (FY) | 2024-12-31 | $10.9M | -$43.4M | -$39.6M | -$39.6M | $41.3M | — |
| FY2023 (FY) | 2023-12-31 | $10.0M | -$47.4M | -$38.4M | -$38.4M | — | — |
3. CRIS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CRIS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Curis Inc. (NASDAQ: CRIS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.66 (+10.17% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
How does CRIS compare to LIMN and BTTC in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRIS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LIMN (Liminatus Pharma Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and BTTC (Black Titan Corporation) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $4.8M). Among the 5-stock peer group, CRIS leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CRIS?
Per CRIS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001108205), Curis Inc. generated $9.4M in revenue (-13.4% YoY), -$7.6M in net income, and -$27.2M in free cash flow against $20.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CRIS trading relative to its 50-day, 200-day, and 52-week technical levels?
CRIS last traded at $0.66 (+10.17% on volume of 1,094,835 shares), positioning the stock -25.00% below its 50-day simple moving average ($0.88) and -92.54% below its 200-day simple moving average ($8.85). Across its 52-week range of $0.33 to $31.80, CRIS sits at the 1.0% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.74).
ROARABLE RATING BRIEF • RQD 27/100 (E)
✓ SEC XBRL & RQD VERIFIED
CRIS — Curis Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Curis Inc. (CRIS) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.66 (+10.17% 1D, market capitalization $4.0M).
- Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Curis Inc. (CRIS) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances)..0B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Curis Inc. (CRIS) reported $9.4M in annual revenue (up from $10.9M in FY2024, -13.4% YoY) and -$7.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($10.0M revenue, -$47.4M net income) through FY2025, CRIS scaled operating cash flow to -$27.2M and free cash flow to -$27.2M, backed by $20.0M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.33 – $31.80 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector-level context is the Health Care / Biological Products classification. The bearish liquidity signal is the sole cross-market transmission channel in the data: because the signal attributes weakening macro tailwinds to the stock's positioning, a prospective investor should note that financing-dependent small caps with negative cash flow are typically more sensitive to tightening liquidity. This is an analytical observation, not a sourced finding about CRIS specifically. Second-order bottlenecks cannot be mapped .
- Key Question #1: Can CRIS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $9.4M and free cash flow of -$27.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CRIS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CRIS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Curis Inc. (CRIS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 23h ago
Curis Stock Price Forecast. Should You Buy CRIS? StockInvest.us report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Curis (CRIS) Announces $8.5M Stock and Warrant Offering to Insti GuruFocus report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Why Curis (NASDAQ: CRIS) Stock Fell 20% After Its $8.5 Million Private Placement kalkine.ca report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
CRIS Q2 2026 Earnings: Narrower-Than-Expected Loss, Yet Shares Slip 3.73% - Low Growth Earnings https://www.dars.gov.et/ report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 1d ago
Curis prices USD 8.5 million offering: Curis stock gains 3.37 percent ad-hoc-news.de report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.dars.gov.et • 1d ago
Curis Inc. (CRIS) Slips 6.21% to $0.61, Testing the Lower Edge of Its Range - Insider Buying Alerts www.dars.gov.et report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 1d ago
MarketBeat estimates USD 1.00 million revenue for Curis stock ad-hoc-news.de report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 1d ago
Curis stock gains 3.37 percent to EUR 0.35: MarketBeat estimates a November 5 report ad-hoc-news.de report covering Curis Inc. (CRIS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CRIS Bull vs. Bear Conversation Board — What's Your Call at $0.66?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRIS 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $0.77 (+28.3%)
📌 Pinned Debate Revenue held near $10M across FY 2023–FY 2025 while net losses narrowed from -$47.4M to -$7.6M.
Picked up a starter position in CRIS in my $100K Virtual Cash book at $0.60. Revenue held near $10M across FY 2023–FY 2025 while net losses narrowed from -$47.4M to -$7.6M.. Trading inside a $0.33–$31.80 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.
RetailWhale_TX 🐂 BULL
Both sides have a point here — CRIS's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $0.51 (-15.0%)
Spot @ $0.60 FCF was negative in every reported year and cash fell from $20.0M to $5.1M alongside an $8.5M equity offering.
Here is the bear case nobody on the bull side wants to address on CRIS: FCF was negative in every reported year and cash fell from $20.0M to $5.1M alongside an $8.5M equity offering.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.